Rosacea

Latest News

FDA Accepts Journey Medical’s NDA for DFD-29 for Rosacea
FDA Accepts Journey Medical’s NDA for DFD-29 for Rosacea

March 18th 2024

The anticipated PDUFA date is November 4, 2024.

National Rosacea Society Launches Seal of Acceptance Program
National Rosacea Society Launches Seal of Acceptance Program

February 13th 2024

Estrogen, Hormone Changes Play Role in Rosacea and Skin Alterations, Study Finds
Estrogen, Hormone Changes Play Role in Rosacea and Skin Alterations, Study Finds

January 17th 2024

Journey Submits New Drug Application for DFD-29 for Rosacea
Journey Submits New Drug Application for DFD-29 for Rosacea

January 5th 2024

Low Levels of Serum GLA in Rosacea Negatively Associated With Erythema, Anxiety, and Depression
Low Levels of Serum GLA in Rosacea Negatively Associated With Erythema, Anxiety, and Depression

December 22nd 2023

More News

© 2024 MJH Life Sciences

All rights reserved.